Patients with renal disease are at risk of further deterioration of renal function and acute tubular necrosis when subjected to anaesthesia and surgery. Optimal fluid loading and careful selection of anaesthetic techniques and agents, appropriate monitoring and the use of mannitol and dopamine assist in the maintenance of renal blood flow and help preserve renal function in these patients. In association with renal failure, physiological changes in other systems result in reduced oxygen supply to the tissues, metabolic disturbances, impairment of the coagulation and immune defence mechanisms and an increased risk of cardiac and cerebrovascular catastrophe. Although many anaesthetic techniques including regional analgesia may be used successfully in these patients caution with most drugs, especially pethidine, phenoperidine, suxamethonium and all nondepolarising neuromuscular relaxants is recommended. Of the volatile anaesthetics currently available, halothane is the agent of choice. Oxygen therapy and close monitoring of cardiorespiratory function are necessary postoperatively.
are predisposed to the development of acute tubular necrosis by the concurrence of anaesthesia, hypovolaemia, hypoxia and acidosis. 3 Table 1 summarises the risk factors for acute tubular necrosis. Normally, 25% of the cardiac output is directed to the kidneys. Renal blood flow is auto regulated , with afferent arteriolar tone increasing linearly within the systolic blood pressure (BP) range of 80-180 mmHg. Increased adrenergic activity and renin, release of which is stimulated by a fall in afferent arteriolar pressure, cause diversion of blood from cortical to juxta-medullary nephrons, resulting in renal conservation of salt and water. Angiotensin, activated by renin, stimulates aldosterone release and by enhancing postglomerular arteriolar tone, 4 maintains glomerular capillary pressure and hence glomerular filtration rate (GFR). Other compensatory mechanisms activated by systemic hypotension and renal hypoperfusion include renal tubular conservation of salt by aldosterone and the release of antidiuretic hormone (ADH). 5 Depression of renal function occurs with most forms of anaesthesia. This is due to effects of the above neurohumoral mechanisms and a decrease in renal blood flow (RBF) and is evidenced by reduced urine production and solute clearance.
Patients at risk of developing acute tubular necrosis can be protected during the operative period in several ways. Maintenance of normal blood volume and renal perfusion pressure are vital. Factors adversely affecting afferent glomerular arteriolar tone should be controlled. These include avoidance of stress, ultra light anaesthesia, alpha adrenergic stimulants and agents which are associated with increased catecholamine activity such as diethyl ether and cyclopropane. 2 The renal protective effect of intravenous mannitol given before the renal haemodynamic disturbance in aortic aneurysm resection, 6 and in jaundiced patients under anaesthesia 7 ,8 is well established. Mannitol (0.5 mg/kg IV) given early, following fluid volume replacement in patients developing acute renal failure may reverse the condition or reduce its severity.9
Frusemide may increase cortical blood flow and by increasing tubular urine flow, reduce intraluminal "sludging"; however, its ability to prevent or abort acute tubular necrosis has not been established. Frusemide should only be used cautiously and in the presence of normovolaemia as it may enhance the nephrotoxicity of other drugs, e.g. antibiotics. 10, 11 Dopamine may be beneficial in incipient renal failure. 12 In normovolaemic, critically ill patients intravenous dopamine 2 Ilg/kg/min causes renal vasodilation and increases urine flow and sodium and creatinine clearance in the absence of other direct haemodynamic effects.13 At doses greater than 10 Ilg/kg/min beneficial renovascular effects may be lost due to alpha adrenergic stimulation. 2 Dobutamine increases RBF secondary to increased cardiac output. 14,15 A protective effect against acute tubular necrosis has not been demonstrated.
Monitoring of patients at risk of developing acute renal failure includes measurement of urine flow with an indwelling urinary catheter, aiming at > 0.5 mllkg/hr. In addition to arterial BP and pulse rate, central venous pressure and pulmonary capillary wedge pressure measurements may help to optimise blood volume, myocardial performance and renal perfusion. Optimal volume loading is particularly important in arterial surgery where aortic clamping, 16 unclampingl7 and third space lossesl 8 may adversely affect renal haemodynamics.
Renal failure -clinical features
Renal failure may be acute or chronic in onset. The latter may be a progression from renal insufficiency when mild azotaemia, anaemia, nocturia and an inability to concentrate the urine are the only noteworthy features of the disease. Physiological abnormalities become more apparent as renal failure progresses. Those of relevance to the anaesthetist include the following.
Hyponatraemia is usually mild, reflecting the dilutional effect of increased total body water. 19 Hyperkalaemia more commonly accompanies acute renal failure than slowly developing renal failure and is associated particularly with tissue trauma, haemolysis, infection and acidosis.20 When serum potassium> 6.0 mmolll, the ECG abnormalities of delayed conduction and peaked T -waves may become apparent. The features of hyperkalaemia are aggravated by concurrent acidosis and hypocalcaemia, and if untreated cardiac arrest may occur. Dextrose 50 g and insulin 15 u IV, sodium bicarbonate 50-100 mmol IV, calcium gluconate 10070, 10 ml IV and calcium exchange resins orally or rectally afford acute protection. 21 Anaesthesia should not be undertaken if serum potassium is
Hypocalcaemia is a frequent accompaniment of renal failure. Hypercalcaemia is uncommon except in acute renal failure associated with rhabdomyolysis 22 and during the diuretic phase of recovery from acute tubular necrosis. 23 Hypermagnesaemia occurs in advanced renal disease 24 but serum values seldom exceed 4 mmolll and therefore impairment of neuromuscular transmission is unlikely. Magnesium containing antacids, MgS04 for eclampsia and magnesium-containing dialysis fluids should be avoided. 25 Uraemia in combination with other metabolic disturbances contributes to the encephalopathy which is characterised by depressed affect, confusion and eventual convulsions and unconsciousness. There is increased sensitivity to all psychotrophic drugs. 26
Glucose intolerance secondary to insulin resistance is not uncommon in uraemia. Control is achieved with insulin and caution is advised with oral hypoglycaemic agents as they are retained in renal failure. 27 Tolbutamide is probably the safest oral hypoglycaemic in uraemia due to its short half-life and hepatic biotransformation. 28 Hypertension is common in renal failure with hypervolaemia, hyperreninaemia and hyperaldosteronism contributing. Cardiac performance may be further compromised by pericarditis.' There is a high incidence of coronary atherosclerosis in advanced renal disease and death due to myocardial infarction and cerebrovascular accident is five times more common in dialysed patients than matched patients with hypertension. '
The haematological aspects of renal failure including the anaemia and coagulopathy are discussed elsewhere in this symposium. 29 The degree of anaemia is variable but usually reasonably well compensated for by increased cardiac output and reduced haemoglobin oxygen affinity due to increased 2,3 diphosphoglycerate levels and the Bohr effect of acidosis.30 In the past there has been a reluctance to transfuse potential renal transplant recipients due to concern about developing sensitivity to histocompatibility (HLA) antigens. Opelz recently confirmed the higher incidence of successful transplants in transfused than nontransfused patients. It is not possible to ascribe a safe haemoglobin level to renal failure patients. If the haemoglobin is greater than 6 g/lOO ml and the patient is asymptomatic, most procedures can be safely performed. If required, preoperative transfusion should occur more than 48 hours before surgery and fresh blood is favoured if available.
The gastrointestinal disturbances of uraemia include anorexia, nausea, vomltmg and gastrointestinal haemorrhage. Gastric hyperacidity is common in chronic haemodyalysis and renal transplant patients.'
Immunological incompetence contributes to the high infection-related mortality associated with acute and chronic renal failure.32 This is not improved by antibiotic prophylaxis. 33 Cellular responses are affected more than humoral immunity and this is evidenced by impaired granulocyte chemotaxis and phagocytosis, and lymphopaenia.
PREPARATION FOR ANAESTHESIA AND SURGERY
Haemodialysis is the most effective means of improving patients with severe renal failure preoperatively. Patients with less severe renal dysfunction must be carefully and individually assessed, and the physiological disturbances outlined above treated appropriately.
A significantly higher incidence of HbsAg positivity has been reported in patients with chronic renal failure on dialysis. 34 Although the titre of HbsAg correlates poorly with infectivity, it is a useful screening test. If positive, precautions against cross-infection should be taken until specialised opinion indicates whether contagion is likely to occur.
Premedication
Patients with uraemic encephalopathy are very sensitive to all psychotrophic drugs. 26 Benzodiazepines are useful because of their oral route of administration and hepatic metabolism. The activity of diazepam may be increased in intensity and duration in renal failure due to reduced protein binding 26 and retention of active metabolites. 35 Oxazepam and tempazepam are recommended as they are short acting and are biotransformed to inactive compounds. 36 Phenothiazines can be used without dosage modification in renal failure/ 6 but hypotension may occur with large doses.
If anticholinergics are considered necessary, the usual dose may be given in renal failure. 3 ? Atropine has no effects on urine flow, GFR or RBF. 38 The intramuscular route should be avoided if a coagulopathy is present.
Both morphine and pethidine in clinical dosage are associated with a reduction in urine volume and increased concentration, related to ADH release. 39 Although reduced plasma binding of morphine in renal failure may occur, no dosage modification is usually necessary. Less than 15070 morphine is excreted in the urine. 40 Pethidine may be used in renal failure, but repeated doses may result in irritability, twitching and seizures. 41 Norpethidine, a urinary metabolite with analgesic and toxic effects, may contribute,42 but correlation between plasma norpethidine levels and toxic effects has not been consistently demonstrated. 43 It may be necessary to give other drugs preoperatively or in conjunction with the premedication. The concurrence of gastric hyperacidity and gastro-oesophageal reflux suggests the preoperative use of an H2 receptor antagonist or antacid. Cimetidine 400 mg 44 or ranitidine 150 mg 45 orally four hours preoperatively are appropriate.
Many patients with renal disease have hypertension. Attention in the past has focused on the need to establish control preoperatively. 46 The avoidance of hypertension at intubation 4 ? and during the operation are equally important. 48 Failure to continue antihypertensive medication throughout the operative period may result in postoperative rebound hypertension. 49 Diazoxide, hydrallazine and methyldopa rely on renal elimination and dosage modification may be necessary. Clonidine, prazosin, propranolol and reserpine are not dependent on renal excretion. 26 GENERAL ANAESTHESIA During induction of anaesthesia special attention should be directed to the maintenance of oxygenation and arterial blood pressure. Preoxygenation is necessitated by the presence of anaemia, reduced cardiorespiratory reserve or when a rapid induction sequence is planned.
Induction agents
Uraemic patients have an increased sensitivity to the hypnotic effect of barbiturates 50 due to reduced plasma protein binding 51 and accelerated delivery to the brain. As the distribution and rate of metabolism of thiopentone are unchanged in renal failure, its duration of effect is not prolonged. It has been suggested that for patients in renal failure, thiopentone should be given in the usual dose but at a slower rate. 52 It has been generally accepted in man that the circulatory depression caused by thiopentone following induction, and with thiopentone, N20, 02 anaesthesia 53 results in a fall in RBF and GFR. Recent animal studies indicate that renovascular autoregulation may be maintained in the presence of moderate doses of thiopentone. 54 Alfathesin has similar cardiovascular effects to thiopentone. In animal studies with alfathesin anaesthesia, RBF was well preserved. 55 The application of alfathesin infusion has been recently reviewed,56 and although no reference to renal insufficiency is made, it would not appear to be a contraindication to its use.
Diazepam is a useful induction agent where preservation of BP is desired. It reduced RBF by only 5% in normovolaemic dogs. 54 Its cumulative effect and elaboration of active metabolites may limit its usefulness. Midazolam, a water-soluble benzodiazepene without active metabolites, has been shown clinically to be suitable for patients with renal disease. Dosage reduction is recommended in this patient group5? as onset of action is shortened and duration of effect prolonged. 58 Recent evidence suggests it depresses mean arterial blood pressure and GFR to a greater extent than thiopentone. 53 Patients with advanced renal disease exhibit the usual cardiovascular responses following ketamine, with increased blood pressure, cardiac output, and heart rate. 59 Animal experiments indicate ketamine maintains or increases renal perfusion. 54 It should be avoided in the hypertensive patient.
Narcotics and neuroleptanalgesia
Narcotics may be used for induction and maintenance of anaesthesia. High-dose fentanyl has received much attention. It is Anaesthesia and Intensive Care, Vol. J I, No. 4, November, 1983 eliminated mainly by the liver with only 10070 appearing in the urine. 60 Animal studies show preservation of RBF despite increased circulating catecholamines. 61 Other studies 62 indicate that large doses of fentanyl and morphine reduce urine flow and free water clearance which suggests ADH release. It seems that in normovolaemic man, large doses of fentanyl or morphine given slowly, with respiratory support, have no detrimental effects on cardiovascular or renal function. Very highdose fentanyl (lOO J.lg/kg) with N20, 02 anaesthesia results in reduced serum catecholamine levels and increased free water clearance. 63 The combination of droperidol 5-10 mg and fentanyl 0.4-0.7 mg, with N20 and 02 following thiopentone induction, has been shown to cause a reduction in GFR and sodium and water excretion. 64 Increased ADH and catecholamine levels are thought to occur with this light form of anaesthesia. These effects are transient and neuroleptanaesthesia has been reported to be suitable for the renal transplant operation 65 and in patients with chronic renal failure undergoing major surgery. 66 Phenoperidine metabolism results in significant amounts of pethidine and norpethidine in the urine. 67 As with pethidine, large doses should be avoided in patients with renal failure.
Buprenorphine, a recently introduced agent with both narcotic agonist and antagonist properties, is characterised by a long duration of action and cardiovascular stability. 68,69 Although data is lacking in man, it appears to be mainly eliminated in the faeces with up to 27% appearing in the urine. 70
Muscle relaxants
Suxamethonium is commonly used to facilitate rapid endotracheal intubation. In normokalaemic patients with or without renal failure, intravenous suxamethonium brings about the release of potassium from skeletal muscle during depolarisation of the muscle membrane and results in a rise of serum potassium of approximately 0.5 mmoIl1. 71 ,72 Suxamethonium has no effect on plasma potassium concentration. 71 concentration. 73 Although the rise is the same in normokalaemic and hyperkalaemic primates given suxamethonium,74 cardiac arrest has been reported following suxamethonium in hyperkalaemic man. 75 It is generally accepted that suxamethonium should be avoided when the serum potassium is greater than 5.5 mmoIl1. 72 ,76 Normocapnoea must be preserved in the hyperkalaemic patient as respiratory acidosis will result in a further increase in potassium concentration. 77 There have been conflicting reports regarding serum cholinesterase activity in renal failure. Ryan 78 was unable to detect significant differences in serum cholinesterase levels in 181 CRF patients receiving different forms of therapy including HD. Suxamethonium infusions 79 and hexafluorenium to prolong suxamethonium 80 have been reported to be satisfactory methods of producing muscle relaxation in renal failure patients. Nondepolarising muscle relaxants have been extensively studied in patients with renal failure.
The effect of gallamine is prolonged in renal failure 81 ,82 due to its reliance on renal excretion. Although a single dose may be tolerated,83 it is generally accepted that renal failure contraindicates its use. D-tubocurarine is the preferred, currently available, nondepolarising relaxant in the renal failure patient 66 ,79,84 as the biliary pathway of elimination is more readily utilised by this agent, increasing fourfold in the anephric state. 85 Plasma binding of d-tubocurarine is unaltered in renal disease. 86 Care must be exercised with dosage and rate of administration in order to avoid the detrimental effect of hypotension on RBF. Potentiation of d-tubucurarine may occur with respiratory and metabolic acidosis,87 acute 88 and chronic hypokalaemia,89,9o volatile anaesthetic agents, hypermagnesaemia, hypocalcaemia, certain antibiotics 87 and in association with frusemide and mannito1. 91 Neuromuscular blockade induced by d-tubocurarine and pancuronium may be antagonised by azathioprine,92 presumably secondary to phosphodiesterase inhibition which facilitates calcium release from the prejunctional membrane. The newly transplanted kidney can excrete d-tubocurarine at a near normal rate. 93 Prolonged paralysis has been reported following the administration of pancuronium to patients with renal failure. 84 ,94,95 The duration of the neuromuscular block may be increased by up to 800/0 in these patients 79 and this reflects a reliance on renal elimination. Biliary excretion and some metabolism are of secondary importance. The role of active pancuronium metabolites in prolonged muscle weakness in patients with renal failure has not been clarified. 84 ,96 Pancuronium has a negligible effect on RBf"l7 and has the advantage over d-tubocurarine of greater cardiovascular stability. It has been reported to be useful in renal failure patients provided a reduction in dosage is employed. 98 Pancuronium, like d-tubocurarine, may be potentiated by hypokalaemia, acidosis and antibiotics. 87 ,100
The use of a nerve stimulator with "train-offour" monitoring as a guide to dose requirement has been suggested to reduce the likelihood of residual curarisation occurring with pancuronium in renal transplant patients. 101 Alcuronium appears to be mainly excreted in the urine and has been reported to have a prolonged effect in association with renal failure. 84 Fazadinium has been suggested, in moderate doses, to be suitable for patients with end-stage renal disease.102 Its elimination half-life is prolonged by 60% in renal failure, which compares favourably with d-tubocurarine (70% )103 and indicates that an alternative elimination pathway is active.
Dimethyl tubocurarine (Metocurine) has been studied in patients with renal failure and considerable variability in duration of action was found. 104 Biliary excretion is much less than with d-tubocurarine and no metabolites have been demonstrated. 105 It is less suitable than d-tubocurarine for patients with end-stage renal disease. 106 Org NC45 (Norcuron), the monoquaternary homologue of pancuronium, is a new competitive neuromuscular blocker with no significant cardiovascular effects. 107 It has a shorter duration of action and a more rapid clearance than pancuronium. Animal experiments demonstrate significant biliary excretion. 108 In man in renal failure the clearance of Org NC45 is reduced to a lesser extent than that of pancuronium. 109 Atracurium dibesylate is currently being evaluated. It has the advantage over other nondepolarising relaxants of a short duration of action due to non-enzymatic degradation (Hofmann elimination) and possibly also noncholinesterase-dependent ester hydrolysis in plasma. 110 Antagonism by neostigmine is not always necessary.lll Animal experiments show that recovery is independent of hepatic and renal elimination, and there is no evidence of cumulation in patients with renal failure. ll2 ,ll3 Preserv'ation of normal cardiovascular parameters is another noteworthy feature. III ,1I4
Of the currently available non depolarising relaxants, d-tubocurarine is the most predictable in end-stage renal disease patients. Monitoring of neuromuscular blockade with a nerve stimulator is strongly advised in this groupll5 as irrespective of the agent used, dosage and frequency of administration will be different from usual. Computer-controlled muscle relaxation l16 has an obvious application in these patients.
Reversal of residual neuromuscular blockade is achieved with neostigmine and atropine. No adjustment of dosage is necessary for atropine. 37 The elimination half-life of neostigmine is significantly prolonged in the anephric patient due to 50% of its clearance normally occurring through the kidneys.ll7 "Recurarisation" due to residual relaxant outlasting the neostigmine effect is an unlikely occurrence in patients with renal failure. 118 Nevertheless, pyridostigmine, with its longer duration of action, has been suggested as an alternative antagonist in renal failure. 119
Volatile anaesthetic agents
Historically, ether and cyclopropane have been avoided in patients with renal insufficiency due to associated renal vasoconstriction secondary to increased adrenergic activity. 5 The nephrotoxic effects of high serum concentrations of inorganic fluoride resulting from the metabolism of methoxyflurane has been well established.12o-122 This agent is contraindicated in patients with renal disease. 66 Halothane has been widely used in patients with renal failure and has been recommended for the renal transplant operation. 66 Halothane, like other volatile anaesthetic agents, reduces RBF, GFR and urine output,123 secondary to reduced arterial blood pressure and increased circulating ADH and catecholamine levels. '24 Deep halothane anaesthesia may reduce RBF by 30070. 125 Concurrent antihypertensive therapy and hypovolaemia secondary to recent haemodialysis may exacerbate halothane hypotension. Supplementation with fentanyl, limiting halothane concentration to less than one per cent, and maintenance of normocapnoea may reduce the incidence and severity of hypotension and catecholamineinduced arrhythmias and help preserve renal autoregulation. 126 The place of enflurane in the anaesthetic management of patients with renal disease has not been fully elucidated. Although it reduces arterial blood pressure, an increase in heart rate usually results in preservation of a stable cardiac outpuL I27 Cardiac arrhythmias associated with endogenous and exogenous catecholamines are less of a problem than with halothane. In normovolaemic patients enflurane anaesthesia has similar effects to halothane, isoflurane and thiopentone, nitrous oxide anaesthesia on RBF, GFR and urine flow. '27 The fact that enflurane enhances tubocurarine and pancuronium-induced neuromuscular blockade '28 suggests it may be useful in the management of patients with severe renal disease by reducing relaxant requirements and potentially reducing the risk of residual weakness secondary to relaxant accumulation.
There have been several reports suggesting enflurane may have a detrimental effect on renal function in patients with normal '29 and abnormal renal function. 130 -132 Enflurane is metabolised to inorganic fluoride to a lesser extent than methoxyflurane and seldom results in serum inorganic fluoride levels greater than 20 /-lmolll. ' Animal experiments show that the nephrotoxic effect of inorganic fluoride is not increased by normal doses of gentamicin 137 but may be with nephrotoxic doses.133 Mannitol and frusemide do not significantly increase urinary inorganic fluoride excretion and are not thought to offer renal protection to this ion. l38 Alkalinisation of the urine may facilitate fluoride elimination and acutely lower plasma fluoride levels. 139, 127 Enflurane has been suggested as a useful supplement to renal transplant anaesthesia, in the latter stages, when the small total dose is unlikely to be nephrotoxic but adequate to reduce the total dose of neuromuscular relaxant required.
Isoflurane undergoes less hepatic biotransformation and its use is associated with lower inorganic fluoride levels than its isomer, enflurane. '4o This, in association with maintenance of stable cardiovascular parameters and low arrhythmogenicity, 141 suggests that it may have a useful place in the management of patients with impaired renal function.
Intermittent positive pressure ventilation (IPPV)
The use of IPPV may affect renal function. IPPV in hypovolaemic patients reduces cardiac output and RBF. The addition of positive end expiratory pressure (PEEP) in critically ill patients reduces urine flow and sodium excretion. '42 Dopamine 5 /-lg/kg/min reverses the deleterious effect of PEEP on the kidney.'43 Animal experiments '44 suggest that hypocapnoea may increase RBF and urine production.
Hypotensive anaesthesia
Hypovolaemic hypotension reduces RBF and may contribute to deterioration of renal function. The effects of induced hypotension with sodium nitroprusside, glyceryl trinitrate and trimetaphan on renal blood flow have produced conflicting results in animals'45-'47 and man. [148] [149] [150] [151] In patients with reduced RBF secondary to nitroprusside-induced hypotension, RBF could be returned to within 20% of control levels without raising mean arterial pressure by giving dopamine 2-3 /-lg/kg/min IV.151 This may be of relevance in patients requiring hypotensive anaesthesia, e.g. clipping cerebral aneurysm, who have impaired renal function. Monitoring urine output is mandatory under these circumstances and it should be remembered that the toxicity of nitroprusside may be increased in the presence of renal insufficiency.152 REGIONAL ANAESTHESIA Regional anaesthesia can be usefully employed in patients with impaired renal function provided no significant coagulation disorder is present and mean arterial pressure is maintained. Uraemic polyneuropathy does not contraindicate the use of local anaesthetic techniques. 153 Arteriovenous fistulae and shunts may be surgically created under brachial plexus anaesthesia; however, a 38070 reduction in duration of the block can be expected. 154 Analgesia of the area occupied by an arterial tourniquet is usually required and the supraclavicular or interscalene approach is therefore favoured. 66 High spinal and epidural anaesthesia may cause a significant fall in mean arterial blood pressure and GFR.39 Careful fluid loading with blood pressure and urine volume monitoring are necessary if renal insufficiency is present. Dopamine (vide supra) may be useful adjunctive therapy, but vasopressors should be avoided. Spinal anaesthesia has been successfully employed for the renal transplant operation. 153
INTRAOPERATIVE MONITORING AND CARE
Measurement and maintenance of arterial blood pressure and urine production (ideally > 0.5 mllkg/hr) aid in ensuring preservation of adequate renal function. An indwelling urinary catheter is therefore usually necessary intraoperatively and postoperatively in patients with renal disease. Central venous and pulmonary capillary wedge pressure measurements are useful when indicated for optimising fluid loading and ventricular performance. Electrocardiographic observation is necessitated by the common presence of cardiac abnormality in this group of patients.
Special attention should be paid to limbs with arteriovenous fistulae and shunts. They should not be used for intravascular cannulae and arterial blood pressure recording. Veins suitable for future fistulae should be preserved. Patients with renal osteodystrophy may be prone to fractures 24 and special care is necessary when they are moved.
POSTOPERATIVE MANAGEMENT
In the postoperative period attention is directed towards maintenance of normovolaemia, stable cardiovascular parameters, urine flow greater than 0.5 mllkg/hr and the provision of supplemental oxygen to offset the often present reduced oxygen availability, and appropriate analgesia. In addition to established regional and narcotic analgesic regimens, tailored to the site of operation and degree of renal impairment ·present, epidural morphine is worthy of consideration. This form of analg~sia has no deleterious effect on renal function or endocrine and metabolic responses following surgery and has some advantages over other techniques. 156 In the immediate postoperative period the presence or absence of residual neuromuscular blockade should be clinically or mechanically assessed. Inadequate ventilation secondary to incomplete reversal of neuromuscular blockade and residual anaesthetic and narcotic effect may be exacerbated by metabolic disturbances and the use of antibiotics. Developing respiratory acidosis may potentiate residual paralysis and precipitate respiratory failure. It is occasionally necessary to continue IPPV postoperatively until adequate muscle power has returned ACKNOWLEDGEMENT I should like to thank Ms Patti Fritz for typing the manuscript.
